Denemek ALTIN - Özgür
Harmonisation moving toward regulatory alignment
Ingredients South Asia
|January 1-15, 2026
AFRICA stands out as a highly attractive frontier for pharmaceutical growth, fueled by rapid population expansion, a rising disease burden, and increasing demand for high-quality healthcare solutions.
However, despite these opportunities, drug registration and approval processes across African countries are complex and heterogeneous. For pharmaceutical companies seeking to enter or scale operations in this evolving market, a clear understanding of the regulatory landscape is essential.
Unlike US FDA or the European Medicines Agency (EMA), Africa lacks a single centralised regulatory authority, with each country overseeing drug approvals through its own National Medicines Regulatory Authority (NMRA), characterised by distinct requirements, documentation formats, and timelines. Although the continent comprises numerous countries with diverse pharmaceutical regulatory systems, recent initiatives such as the African Medicines Agency (AMA) and regional harmonisation efforts are gradually moving toward greater regulatory alignment.
Most African countries accept the CTD dossier format for drug registration; however, each nation operates through its own National Regulatory Authority (NRA), such as NAFDAC in Nigeria or SAHPRA in South Africa. These authorities are responsible for overseeing product registration, importation licensing, compliance with Good Manufacturing Practices (GMP), and pricing and reimbursement regulations.
Regional Regulatory Frameworks
Africa's regulatory environment is gradually evolving from fragmented national systems toward greater harmonisation, driven mainly by the African Medicines Agency (AMA) and Regional Economic Communities (RECs) such as the EAC and ECOWAS. Through initiatives like the African Medicines Regulatory Harmonisation (AMRH) programme, these efforts emphasise common standards for quality medicines and seek to enable unified approval pathways, joint assessments, and mutual recognition. Nevertheless, significant challenges persist in achieving full implementation across diverse sectors, including digital finance and energy.
Bu hikaye Ingredients South Asia dergisinin January 1-15, 2026 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Ingredients South Asia'den DAHA FAZLA HİKAYE
Ingredients South Asia
Sustainability becoming cornerstone of cosmetics industry
There has been an incredible shift in cosmetics over the last few decades.
5 mins
January 1-15, 2026
Ingredients South Asia
"We mostly relied on customer funding to grow"
Greenspace Herbs, a leading botanical ingredients company is gearing up for its commercial launch of Quantum Ayurveda, an advanced technology platform that enhances traditional herbal ingredients using quantum resonance principles. For us innovation represents the first successful commercialisation of quantum-enhanced botanical supplements, bridging ancient Ayurvedic wisdom with cutting-edge scientific methodology, said SHAFIULLA NURUDDIN HIREHAL, director, Greenspace Herbs, in an email interaction with NANDITA VIJAYASIMHA. Excerpts:
6 mins
January 1-15, 2026
Ingredients South Asia
Harmonisation moving toward regulatory alignment
AFRICA stands out as a highly attractive frontier for pharmaceutical growth, fueled by rapid population expansion, a rising disease burden, and increasing demand for high-quality healthcare solutions.
4 mins
January 1-15, 2026
Ingredients South Asia
Increasing penetration of clean-label, natural ingredients
The food ingredients sector plays a pivotal role in the global food and beverages value chain, providing essential components that enhance taste, texture, nutrition, safety, and shelf life of food products.
3 mins
January 1-15, 2026
Ingredients South Asia
India's expertise can fill critical gaps in Africa
AFRICA'S demand for medicines is rising faster than almost anywhere else in the world. Population growth, urbanisation and the steady increase in noncommunicable diseases such as diabetes, cardiovascular conditions and cancer are reshaping pharmaceutical consumption. As African governments expand health-insurance coverage and essential-medicine lists, public procurement of medicines is increasing sharply across the continent. Yet Africa's pharmaceutical ingredients sector remains overwhelmingly import-dependent, with more than 95% of active pharmaceutical ingredients (APIs) sourced from Asia. The Covid-19 pandemic exposed the fragility of this model, as global supply disruptions translated into local shortages. Combined with the rising burden of communicable and noncommunicable diseases, these pressures have elevated API manufacturing from a longstanding policy aspiration to a strategic public-health and economic priority.
4 mins
January 1-15, 2026
Ingredients South Asia
Industry to discuss APIs scheme with Korea to attract investment
IN a major boost to the Indian bulk drugs industry, Indian pharma industry and exporters will discuss the production linked incentive (PLI) scheme for active pharmaceutical ingredients (APIs) with the Korean pharma industry at the upcoming 16th Edition of KOREA PHARM & BIO 2026 to attract Korean investment into India's pharmaceutical and API sector. Besides this, opportunities for business partnerships and collaborations will also be discussed.
2 mins
January 1-15, 2026
Ingredients South Asia
India gains ground in excipients globally: Sinha
INDIA is gaining ground as a reliable excipient supplier globally as Indian manufacturers are adding capacity and improving regulatory compliance.
1 min
January 1-15, 2026
Ingredients South Asia
Future-ready, innovation driven enterprise in API intermediates
Sichuan Dingke Pharmaceutical Co., Ltd. is a young, ambitious enterprise founded in 2022.
2 mins
January 1-15, 2026
Ingredients South Asia
DoP extends timeline for submission under PLI scheme
THE Department of Pharmaceuticals (DOP) has extended the timeline for the industry to submit their applications for support under the production linked incentive (PLI) scheme for bulk drugs to produce key ingredients of broad-spectrum carbapenem antibiotic meropenem and antiretroviral drug ritonavir.
2 mins
January 1-15, 2026
Ingredients South Asia
Ministry issues draft amendment to remove cough syrups from Schedule K
THE Union health ministry has proposed an amendment to remove cough syrups from Schedule K, to make its sales strictly under prescription of a medical practitioner.
1 mins
January 1-15, 2026
Listen
Translate
Change font size
